Comparison of clinical efficacy of tegafur combined with oxaliplatin and gemcitabine combined with cisplatin in the treatment of advanced trinegative breast cancer

Abstract

Objective To analyze the clinical efficacy and safety of tegafur combined with oxaliplatin and gemcitabine combined with cisplatin in the treatment of advanced triple negative breast cancer. Methods Seventy-eight female patients with metastatic triple negative breast cancer who has afailed treatment with anthracycline/taxanes from January 1, 2012 to December 31, 2015 in PLA 309 Hospital were randomly divided into SOX group (38 cases) and GP group (40 cases) by computer generated random numbers. Results The objective response rates of SOX group and GP group were 31.5% (12/38) and 32.5% (13/40), and the disease control rates were 65.8% (25/38) and 70.0% (28/40), respectively.There was no significant difference between the two groups (P value was 1.000 and 0.809). The median progression-free survival time of GP group and SOX group was 6.6 and 5.5 months respectively, and there was a significant difference between the two groups (P=0.044). Adverse reactions in both groups included bone marrow suppression, gastrointestinal reactions and so on.The incidence rate of digestive tract reaction was 23.7% (9/38) in SOX group and 27.5% (11/40) in GP group.There was no significant difference between the two groups (P=0.699). The incidence rate of bone marrow suppression was 28.9% (11/38) and 30.0% (12/40), respectively.There was no significant difference between the two groups (P=0.920). Conclusion Tegafur combined with oxaliplatin and gemcitabine combined with cisplatin are effective drugs for the treatment of metastatic triple negative breast cancer, and the adverse reactions are tolerable. Key words: Triple negative breast cancer; Tegafur; Oxaliplatin; Gemcitabine; Cisplatin